Patents by Inventor Frédéric LALLEMAND
Frédéric LALLEMAND has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170165368Abstract: Composition comprising at least one fatty acid glycerol ester for use during or after a vitrectomy procedure, said composition being bioresorbable, being injectable in the vitreous cavity, having a density below 1, more preferably comprised between 0.90 and 1, or a density above 1 more preferably between 1 and 1.5; having a surface tension of less than 50 dynes/cm more preferably ranging from 20 and 30 dynes/cm, being not susceptible to emulsify into droplets when injected; method for treating a retinal disorder involving the use of said composition.Type: ApplicationFiled: February 23, 2017Publication date: June 15, 2017Inventors: Jean-Sebastien Garrigue, Frederic Lallemand, Jeffrey Heier
-
Patent number: 9616016Abstract: A composition includes at least one fatty acid glycerol ester for use during or after a vitrectomy procedure, the composition being bioresorbable, being injectable in the vitreous cavity, having a density below 1, more preferably between 0.90 and 1, or a density above 1, more preferably between 1 and 1.5; having a surface tension of less than 50 dynes/cm more preferably ranging from 20 and 30 dynes/cm, being not susceptible to emulsify into droplets when injected; method for treating a retinal disorder involving the use of the composition.Type: GrantFiled: November 19, 2010Date of Patent: April 11, 2017Assignee: SANTEN SASInventors: Frédéric Lallemand, Jean-Sébastien Garrigue, Jeffrey Heier
-
Patent number: 9555045Abstract: A composition for use in treating corneal and conjunctival lesions, includes a prostaglandin F2alpha or analogue, in a therapeutic amount, the composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative. A method for treating surface ocular conditions in a patient in need thereof, includes administering an effective amount of the composition.Type: GrantFiled: November 19, 2010Date of Patent: January 31, 2017Assignee: SANTEN SASInventors: Jean-Sebastien Garrigue, Frederic Lallemand, Philippe Daull, Christophe Baudouin
-
Patent number: 9364461Abstract: The present invention relates to new processes for the preparation of oil-in-water emulsions useful in ophthalmic applications. In particular, processes are provided that include preparing a pre-concentrate of the oil-in-water emulsion, and diluting the pre-concentrate obtained to form the desired oil-in-water emulsion. The present invention also provides pharmaceutical compositions comprising an oil-in-water emulsion prepared by an inventive process, and methods of using these compositions for the treatment of an eye disease or condition.Type: GrantFiled: December 21, 2007Date of Patent: June 14, 2016Assignee: SANTEN SASInventors: Gregory Lambert, Frederic Lallemand, Laura Rabinovich-Guilatt, Pascal Candillon, Julien Lafosse
-
Publication number: 20160082107Abstract: Compositions containing quaternary compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, and the composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Also, ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions.Type: ApplicationFiled: November 17, 2015Publication date: March 24, 2016Inventors: Laura RABINOVICH-GUILATT, Gregory LAMBERT, Frederic LALLEMAND, Betty PHILIPS
-
Patent number: 9220694Abstract: Compositions containing quaternary compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, and the composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Also, ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions.Type: GrantFiled: August 2, 2013Date of Patent: December 29, 2015Assignee: SANTEN SASInventors: Laura Rabinovich-Guilatt, Gregory Lambert, Frederic Lallemand, Betty Philips
-
Patent number: 9132071Abstract: Compositions containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, where composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Ophthalmic oil-in-water emulsions containing such compositions, and the ophthalmic emulsions being are useful for eye care or for the treatment of eye conditions.Type: GrantFiled: January 30, 2008Date of Patent: September 15, 2015Assignee: SANTEN SASInventors: Laura Rabinovich-Guilatt, Gregory Lambert, Frederic Lallemand, Betty Philips
-
Patent number: 9107822Abstract: The invention relates to a composition for administering with a sustained release kinetic a therapeutically effective amount of a therapeutic agent to a subject in need thereof for treating diseases or conditions of the eye, wherein the composition is an water-in-oil type emulsion comprising an oil phase, a lipophilic surfactant dissolved in the oil phase, an aqueous phase dispersed in the oil phase, a hydrophilic therapeutic agent dissolved in the aqueous dispersed phase, and wherein the composition is intraocularly injectable, wherein the composition has a density lower than 1. The invention also relates to a pharmaceutical composition or to a medicament comprising the composition of the invention, and to a method for treating a condition or disease of the eye comprising administering a therapeutic amount of the composition of the invention. The invention also relates to a device comprising the composition of the invention.Type: GrantFiled: September 2, 2011Date of Patent: August 18, 2015Assignee: SANTEN SASInventors: Frederic Lallemand, Jean-Sebastien Garrigue, Betty Philips
-
Patent number: 9089480Abstract: A colloidal anionic oil-in-water emulsion includes a prostaglandin, an oil having a iodine value ?2, a surfactant and water, provided the anionic oil-in-water emulsion does not contain polyvinyl alcohol. The use of the anionic oil-in-water emulsions for enhancing the stability of the prostaglandins, for the treatment of ocular hypertension and/or glaucoma, for promoting growth of eyelashes and/or for treating eyelash hypotrichosis is also described.Type: GrantFiled: March 4, 2010Date of Patent: July 28, 2015Assignee: SANTEN SASInventors: Frederic Lallemand, Betty Phillips, Jean-Sebastien Garrigue
-
Patent number: 9072750Abstract: The invention relates to a composition for use in treating corneal and conjunctival lesions, wherein the composition comprises a prostaglandin F2alpha or analogue, in a therapeutic amount, said composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative; the invention also relates to a method for treating surface ocular conditions in a patient in need thereof, comprising administering a composition of the invention.Type: GrantFiled: November 19, 2010Date of Patent: July 7, 2015Assignee: SANTEN SASInventors: Jean-Sébastien Garrigue, Frédéric Lallemand, Philippe Daull, Christophe Baudouin
-
Publication number: 20150025020Abstract: The present invention relates to a self-preserved oil dispersion. Especially, the present invention relates to a self-preserved oil dispersion including a dispersed oil phase, an aqueous phase and at least one surfactant, wherein said oil dispersion comprises boric acid in an amount ranging from 0.005% to 0.075% in weight of the total weight of the oil dispersion, said amount of boric acid being a preservative effective amount so that the oil dispersion has a preservative activity.Type: ApplicationFiled: February 22, 2013Publication date: January 22, 2015Inventors: Jean-Sébastien Garrigue, Frédéric Lallemand, Betty Philips
-
Patent number: 8623852Abstract: The present invention relates to a new therapeutic approach for the treatment of eye diseases or conditions that allows for the delivery of corticosteroids to the eye's surface but does not cause any of the usual side effects associated with topical administration of corticosteroids. More specifically, the present invention provides methods of treatment involving the administration of a corticosteroid prodrug, such as dexamethasone palmitate, to the surface of the eye. Also provided are pharmaceutical compositions and kits for carrying out such methods of treatment.Type: GrantFiled: December 3, 2008Date of Patent: January 7, 2014Assignee: Santen SASInventors: Gregory Lambert, Laura Rabinovich, Frederic Lallemand, Betty Philips
-
Publication number: 20130337019Abstract: Compositions containing quaternary compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, and the composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Also, ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions.Type: ApplicationFiled: August 2, 2013Publication date: December 19, 2013Applicant: NOVAGALI PHARMA SAInventors: LAURA RABINOVICH-GUILATT, GREGORY LAMBERT, FREDERIC LALLEMAND, BETTY PHILIPS
-
Patent number: 8524779Abstract: Composition containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, the composition including at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions are also disclosed.Type: GrantFiled: April 28, 2011Date of Patent: September 3, 2013Assignee: Novagali Pharma SAInventors: Laura Rabinovich-Guilatti, Gregory Lambert, Frederic Lallemand, Betty Philips
-
Patent number: 8512687Abstract: Oil-in-water emulsion including a non-steroidal anti-inflammatory drug and a quaternary ammonium halide useful for the prevention and treatment of inflammation in the eye, and process for manufacturing thereof.Type: GrantFiled: July 29, 2010Date of Patent: August 20, 2013Assignee: Novagali Pharma SAInventors: Grégory Lambert, Laura Rabinovich-Guilatt, Frédéric Lallemand, Jean-Sébastien Garrigue, Betty Philips
-
Publication number: 20130164285Abstract: The invention relates to a composition for administering with a sustained release kinetic a therapeutically effective amount of a therapeutic agent to a subject in need thereof for treating diseases or conditions of the eye, wherein the composition is an water-in-oil type emulsion comprising an oil phase, a lipophilic surfactant dissolved in the oil phase, an aqueous phase dispersed in the oil phase, a hydrophilic therapeutic agent dissolved in the aqueous dispersed phase, and wherein the composition is intraocularly injectable, wherein the composition has a density lower than 1. The invention also relates to a pharmaceutical composition or to a medicament comprising the composition of the invention, and to a method for treating a condition or disease of the eye comprising administering a therapeutic amount of the composition of the invention. The invention also relates to a device comprising the composition of the invention.Type: ApplicationFiled: September 2, 2011Publication date: June 27, 2013Applicant: NOVAGALI PHARMA SAInventors: Frederic Lallemand, Jean-Sebastien Garrigue, Betty Philips
-
Publication number: 20120238536Abstract: Composition comprising at least one fatty acid glycerol ester for use during or after a vitrectomy procedure, said composition being bioresorbable, being injectable in the vitreous cavity, having a density below 1, more preferably comprised between 0.90 and 1, or a density above 1 more preferably between 1 and 1.5; having a surface tension of less than 50 dynes/cm more preferably ranging from 20 and 30 dynes/cm, being not susceptible to emulsify into droplets when injected; method for treating a retinal disorder involving the use of said composition.Type: ApplicationFiled: November 19, 2010Publication date: September 20, 2012Applicant: NOVAGALI PHARMA SAInventors: Jean-Sebastien Garrigue, Frederic Lallemand, Jeffrey Heier
-
Publication number: 20120225939Abstract: The invention relates to a composition for use in treating corneal and conjunctival lesions, wherein the composition comprises a prostaglandin F2alpha or analogue, in a therapeutic amount, said composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative; the invention also relates to a method for treating surface ocular conditions in a patient in need thereof, comprising administering a composition of the invention.Type: ApplicationFiled: November 19, 2010Publication date: September 6, 2012Applicant: NOVAGALI PHARMA SAInventors: Jean-Sebastien Garrigue, Frederic Lallemand, Philippe Daull, Christophe Baudouin
-
Publication number: 20120058187Abstract: A composition is described herein for administering with a sustained release kinetic a therapeutically effective amount of a therapeutic agent to a subject in need thereof for treating diseases or conditions of the eye, wherein the composition is an water-in-oil type emulsion comprising an oil phase, a lipophilic surfactant dissolved in the oil phase, an aqueous phase dispersed in the oil phase, a hydrophilic therapeutic agent dissolved in the aqueous dispersed phase, and wherein the composition is intraocularly injectable, wherein the composition has a density lower than 1. Some embodiments also relate to a pharmaceutical composition or to a medicament comprising a composition described herein, and to a method for treating a condition or disease of the eye comprising administering a therapeutic amount of a composition described herein.Type: ApplicationFiled: September 3, 2010Publication date: March 8, 2012Applicant: NOVAGALI PHARMA SAInventors: Frédéric LALLEMAND, Jean-Sébastien GARRIGUE
-
Publication number: 20110319488Abstract: A colloidal anionic oil-in-water emulsion includes a prostaglandin, an oil having a iodine value ?2, a surfactant and water, provided the anionic oil-in-water emulsion does not contain polyvinyl alcohol. The use of the anionic oil-in-water emulsions for enhancing the stability of the prostaglandins, for the treatment of ocular hypertension and/or glaucoma, for promoting growth of eyelashes and/or for treating eyelash hypotrichosis is also described.Type: ApplicationFiled: March 4, 2010Publication date: December 29, 2011Applicant: NOVAGALI PHARMA SAInventors: Frederic Lallemand, Betty Phillips, Jean-Sebastien Garrigue